The objective of this study was to investigate health-related quality of life (HRQOL), symptom burden, and comorbidity profile in long-term acute promyelocytic leukemia (APL) survivors treated with standard chemotherapy. Overall, 307 long-term APL survivors were invited to participate. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and compared with that of age and sex-matched controls from the general population. Symptom burden was assessed with the MD Anderson Symptom Inventory (MDASI) questionnaire and comorbidity profile was also investigated. Median follow-up time since diagnosis was 14.3 years (interquartile range: 11.1-16.9 years). APL survivors had a statistically and clinically meaningful worse score for the role physical scale of the SF-36 (-9.5; 95% CI, -15.7 to -3.2, P = 0.003) than their peers in the general population. Fatigue was reported as moderate to severe by 29% of patients and 84.4% reported at least one comorbidity. Prevalence of comorbidity in APL survivors was higher than that reported by the general population. Also, marked variations were found in the HRQOL profile by number of comorbidities. Even many years after treatment ends, APL survivors treated with standard chemotherapy do not fully recover as they report HRQOL limitations and a substantial burden of symptoms.

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia / Efficace, F.; Breccia, M.; Avvisati, G.; Cottone, F.; Intermesoli, T.; Borlenghi, E.; Carluccio, P.; Rodeghiero, Flavio; Fabbiano, F.; Luppi, M.; Romani, Cristina; Sborgia, M.; D'Ardia, S.; Nobile, F.; Cantore, N.; Crugnola, M.; Nadali, G.; Vignetti, M.; Amadori, S.; Lo Coco, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 33:7(2019), pp. 1598-1607. [10.1038/s41375-018-0325-4]

Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia

Efficace F.;Breccia M.;Cottone F.;RODEGHIERO, FLAVIO;Romani, Cristina;Vignetti M.;Amadori S.;Lo Coco F.
2019

Abstract

The objective of this study was to investigate health-related quality of life (HRQOL), symptom burden, and comorbidity profile in long-term acute promyelocytic leukemia (APL) survivors treated with standard chemotherapy. Overall, 307 long-term APL survivors were invited to participate. HRQOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and compared with that of age and sex-matched controls from the general population. Symptom burden was assessed with the MD Anderson Symptom Inventory (MDASI) questionnaire and comorbidity profile was also investigated. Median follow-up time since diagnosis was 14.3 years (interquartile range: 11.1-16.9 years). APL survivors had a statistically and clinically meaningful worse score for the role physical scale of the SF-36 (-9.5; 95% CI, -15.7 to -3.2, P = 0.003) than their peers in the general population. Fatigue was reported as moderate to severe by 29% of patients and 84.4% reported at least one comorbidity. Prevalence of comorbidity in APL survivors was higher than that reported by the general population. Also, marked variations were found in the HRQOL profile by number of comorbidities. Even many years after treatment ends, APL survivors treated with standard chemotherapy do not fully recover as they report HRQOL limitations and a substantial burden of symptoms.
Adult; Aged; Case-Control Studies; Comorbidity; Female; Follow-Up Studies; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Patient Reported Outcome Measures; Prevalence; Prognosis; Sickness Impact Profile; Surveys and Questionnaires; Survival Rate; Survivors; Time Factors; Quality of Life; Severity of Illness Index
01 Pubblicazione su rivista::01a Articolo in rivista
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia / Efficace, F.; Breccia, M.; Avvisati, G.; Cottone, F.; Intermesoli, T.; Borlenghi, E.; Carluccio, P.; Rodeghiero, Flavio; Fabbiano, F.; Luppi, M.; Romani, Cristina; Sborgia, M.; D'Ardia, S.; Nobile, F.; Cantore, N.; Crugnola, M.; Nadali, G.; Vignetti, M.; Amadori, S.; Lo Coco, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 33:7(2019), pp. 1598-1607. [10.1038/s41375-018-0325-4]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1330023
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact